ArticleCancer research2020
A Circle RNA Regulatory Axis Promotes Lung Squamous Metastasis via CDR1-Mediated Regulation of Golgi Trafficking.
Open access · greenAbstract read
In one paragraph
Article in Cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 46 citations in OpenAlex.
- Targeting intrinsic and CAF-mediated signaling by PI3Kα inhibitor CYH33 attenuated metastasis in lung squamous cell carcinoma.Acta pharmacologica Sinica · 2026Article
- Pathobiology and clinical significance of malignant pleural effusions.EMBO molecular medicine · 2026Review
- Circular RNAs: from transcriptional noise to engineered therapeutics.Frontiers in epigenetics and epigenomics · 2026Review
- Tumor suppressors in Sox2-mediated lung cancers promote distinct cell-intrinsic and immunologic remodeling.JCI insight · 2025Article
- Targeting hypoxia-mediated chemo-immuno resistance by a hybrid NBDHEX-Pt(IV) prodrug via declining nuclear STING1-promoted AhR-CIN in human lung squamous cell carcinoma.Translational oncology · 2025Article
- Circular RNA Cdr1as inhibits proliferation and delays injury-induced regeneration of the intestinal epithelium.JCI insight · 2024Article
- Nanotechnology-Aided Advancement in Combating the Cancer Metastasis.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Nanotechnology-aided advancement in the combating of cancer metastasis.Cancer metastasis reviews · 2022Review
- Identification of the circRNA-miRNA-mRNA Prognostic Regulatory Network in Lung Adenocarcinoma.Genes · 2022Article
- Targeting brain lesions of non-small cell lung cancer by enhancing CCL2-mediated CAR-T cell migration.Nature communications · 2022Article
- hsa_circ_0005358 suppresses cervical cancer metastasis by interacting with PTBP1 protein to destabilize CDCP1 mRNA.Molecular therapy. Nucleic acids · 2022Article
- Bioinformatics Analysis of the MicroRNA-Metabolic Gene Regulatory Network in Neuropathic Pain and Prediction of Corresponding Potential Therapeutics.Journal of molecular neuroscience : MN · 2022Article
- Revisiting miRNA Association with Melanoma Recurrence and Metastasis from a Machine Learning Point of View.International journal of molecular sciences · 2022Review
- Article
- Identification of miRNA signature for predicting the prognostic biomarker of squamous cell lung carcinoma.PloS one · 2022Article
- A review on the role of miR-671 in human disorders.Frontiers in molecular biosciences · 2022Review
- Research progress on the role and mechanism of miR-671 in bone metabolism and bone-related diseases.Frontiers in oncology · 2022Review
- Mapping lung squamous cell carcinoma pathogenesis through in vitro and in vivo models.Communications biology · 2021Review
- Circular RNA circ_001422 promotes the progression and metastasis of osteosarcoma via the miR-195-5p/FGF2/PI3K/Akt axis.Journal of experimental & clinical cancer research : CR · 2021Article
- Circular RNAs in Lung Cancer: Recent Advances and Future Perspectives.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 2 institutions in 1 country.
Emily B HarrisonLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.ORCID 0000-0002-6934-3875
Alessandro PorrelloLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
Brittany M BowmanLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.ORCID 0000-0003-2054-6169
Adam R BelangerDivision of Pulmonary and Critical Care Medicine, University of North Carolina, Chapel Hill, North Carolina.
Gabriella YacovoneLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
Salma H AzamLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.ORCID 0000-0003-1861-0475
Ian A WindhamDepartment of Cell Biology and Physiology, University of North Carolina, Chapel Hill, North Carolina.ORCID 0000-0002-4486-6602
Subrata K GhoshLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
Menglin WangCenter for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina.
Nicholas MckenzieLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
Trent A WaughLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
Amanda E D Van SwearingenLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.ORCID 0000-0002-4287-9741
Stephanie M CohenLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.ORCID 0000-0003-2982-3265
Devon G AllenMarsico Lung Institute/Cystic Fibrosis Center, University of North Carolina, Chapel Hill, North Carolina.
Tyler J GoodwinCenter for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina.ORCID 0000-0003-2046-7794
Teresa MascenikMarsico Lung Institute/Cystic Fibrosis Center, University of North Carolina, Chapel Hill, North Carolina.
James E BearDepartment of Cell Biology and Physiology, University of North Carolina, Chapel Hill, North Carolina.
Sarah CohenDepartment of Cell Biology and Physiology, University of North Carolina, Chapel Hill, North Carolina.ORCID 0000-0003-2982-3265
Scott H RandellDepartment of Cell Biology and Physiology, University of North Carolina, Chapel Hill, North Carolina.
Pierre P MassionVanderbilt Ingram Cancer Center, Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0003-0647-0559
Michael B MajorLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.ORCID 0000-0002-6753-8513
Leaf HuangCenter for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina.
Chad V PecotLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina. pecot@email.unc.edu.
University of North Carolina at Chapel Hill · USVanderbilt University Medical Center · US
Funding
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5MRe-Entry Supplement: Investigation of Oral Microbial Enzymes for the Detection and Treatment of Periodontal DiseaseUL1TR002489 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, SHAHEEN, NICHOLAS J · 2018 to 2022
$48.6MVector CoreP30DK065988 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Richard Charles Boucher, Martina Gentzsch · 2004 to 2026
$26.5MTargeting the MEKK2-ERK5 Signaling Node in Triple Negative Breast CancerU54CA156733 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LINNAN, LAURA A · 2010 to 2020
$9.7MTRAINING IN RESPIRATORY AND ENVIRONMENTAL MEDICINET32HL007106 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BOUCHER, RICHARD CHARLES, DOERSCHUK, CLAIRE M · 1985 to 2021
$7.3MNRSA IN GENETICST32GM007092 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SEKELSKY, JEFF J. · 1985 to 2019
$5.9MSystematic Analysis of the Actin Cytoskeleton and Directed Cell MigrationR35GM130312 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JAMES E BEAR · 2019 to 2026
$4.8MCAROLINA CANCER NANOTECHNOLOGY TRAINING PROGRAM (C-CNTP)T32CA196589 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Gaorav P. Gupta, ALEXANDER V KABANOV · 2015 to 2026
$4.5MMolecular mechanisms of intra- and inter-cellular fatty acid traffickingR35GM133460 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Sarah Cohen · 2019 to 2026
$2.9MImmune Regulation of Lung Squamous MetastasisR01CA215075 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PECOT, CHAD V · 2017 to 2021
$2.0MTraining in Mechanistic, Interdisciplinary Studies of Biological SystemsT32GM119999 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI RAMSDEN, DALE A · 2017 to 2021
$1.2MDevelopment of EFTX-001 to target KRAS mutations in cancerR41CA246848 · NCI · ENFUEGO THERAPEUTICS INC. · PI PECOT, CHAD V · 2020 to 2020
$225kNCATS NIH HHS UL1 TR002489NCI NIH HHS P30 CA016086NCI NIH HHS R01 CA215075NCI NIH HHS R41 CA246848NCI NIH HHS T32 CA196589NCI NIH HHS U54 CA156733NHLBI NIH HHS T32 HL007106NIDDK NIH HHS P30 DK065988NIGMS NIH HHS R35 GM130312NIGMS NIH HHS R35 GM133460NIGMS NIH HHS T32 GM007092NIGMS NIH HHS T32 GM119999
Abstract
Lung squamous carcinoma (LUSC) is a highly metastatic disease with a poor prognosis. Using an integrated screening approach, we found that miR-671-5p reduces LUSC metastasis by inhibiting a circular RNA (circRNA), CDR1as. Although the putative function of circRNA is through miRNA sponging, we found that miR-671-5p more potently silenced an axis of CDR1as and its antisense transcript, cerebellar degeneration related protein 1 (CDR1). Silencing of CDR1as or CDR1 significantly inhibited LUSC metastases and CDR1 was sufficient to promote migration and metastases. CDR1, which directly interacted with adaptor protein 1 (AP1) complex subunits and coatomer protein I (COPI) proteins, no longer promoted migration upon blockade of Golgi trafficking. Therapeutic inhibition of the CDR1as/CDR1 axis with miR-671-5p mimics reduced metastasis
Indexed as
Adaptor Protein Complex 1AnimalsAutoantigensCarcinoma, Squamous CellCell Line, TumorCell MovementCoat Protein Complex IEndoplasmic ReticulumFemaleGolgi ApparatusHumansHyaluronic AcidLung NeoplasmsMiceMice, NudeMicroRNAsAdaptor Protein Complex 1AutoantigensCDR1 protein, humanCoat Protein Complex IHyaluronic Acidlong non-coding RNA CDR1AS, humanMicroRNAsMIRN671 microRNA, humanNeoplasm ProteinsNerve Tissue ProteinsRNA, CircularRNA, Long Noncoding
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.